Many FXR agonists, featuring steroidal or nonsteroidal scaffolds, have been identified, and many of them are in preclinical and clinical phases for the treatment of different hepatic and metabolic diseases [6,7,8]. This evidence concerns the gene NR1H4 and Other metabolic disease.